Protein geranylgeranyltransferase type I (GGTase-I) is responsible for the prenylation of several proteins, such as the RHO family proteins, that contribute to tumor development and metastasis. Inhibiting GGTase-I, to interfere with the activity of the RHO family proteins, has been viewed as a potential strategy for cancer therapy. Several inhibitors against GGTase-I have been developed and a clinical trial is ongoing. 1 However, the efficacy and toxicity among different GGTase-I inhibitors have varied widely, which have made it difficult to distinguish mechanism-related effects from off-target effects. 2, 3 The rationale for targeting GGTase-I was supported by genetic studies in mice: inactivating Pggt1b, the gene encoding GGTase-I, reduced tumor development and improved survival in mice with K-RAS-induced lung cancer. 4 Nothing is yet known about the impact of inhibiting GGTase-I on the development of hematologic malignancies.
To approach this issue, we bred mice harboring a conditional knockout allele of Pggt1b (Pggt1b fl ), 4 a latent Cre-inducible Kras2 LSL allele (K) and an interferon-inducible Mx1-Cre transgene (M). Injection of double-stranded RNA (pI-pC) into KM mice switches on the expression of oncogenic K-RAS (K-RAS G12D ) in hematopoietic cells and results in a progressive and lethal myeloproliferative disease (MPD) with myeloid leukocytosis, tissue infiltration, hepatosplenomegaly and hypersensitivity of hematopoietic cells to growth factors; 10-30% also develop thymic lymphoma/T-cell acute lymphoblastic leukemia (T-ALL). [5] [6] [7] However, the Mx1-Cre transgene triggers Cre and K-RAS G12D expression in many other tissues and results in lung adenocarinoma and large squamous papillomas in the gastrointestinal tract and skin. 6, 7 We argued that the widespread tumor formation in pI-pC-injected KM mice would complicate efforts to define the impact of GGTase-I deficiency on the development of K-RASinduced MPD. To attempt to overcome this issue, we collected fetal liver cells from Pggt1b G12D allele and inactivation of the Pggt1b fl allele in peripheral blood of the transplanted mice. Genotyping was performed as described. 4 (c) Western blots of whole-cell lysates from bone marrow using an antibody recognizing nonprenylated RAP1A (sc-1482; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Actin was used as a loading control (A2066; Sigma-Aldrich). Western blots were performed as described.
fetal liver cells harboring either the K allele or the M transgene, but not both. We asked two questions: what are the phenotypes of mice expressing K-RAS G12D exclusively in hematopoietic cells (that is, pI-pC-injected recipients of Pggt1b fl/ þ KM fetal liver cells)? Would those phenotypes be affected by GGTase-I inactivation (that is, in pI-pC-injected recipients of Pggt1b KM (n ¼ 13) and control mice (n ¼ 11). Black tick marks indicate mice removed from experiment for tissue analyses. (e and f) Bone marrow cells (n ¼ 4/genotype) were cultured in duplicate wells in methylcellulose medium in the presence of GM-CSF (e) or EPO (f): CFU-GM and BFU-E were counted after 9 and 7 days, respectively. Colony assays were performed as described. Letters to the Editor PI-pC injections in recipients of Pggt1b fl/ þ KM cells resulted in leukocytosis, splenomegaly, an increased proportion of CD13 and CD11b-positive cells and reduced proportion of CD3-positive cells in peripheral blood (Figures 2a-c) , and a median survival of 82 days (Figure 2d) . Moreover, bone marrow cells produced more colonyforming unit granulocyte-macrophage (CFU-GM) and burst-forming unit erythroid (BFU-E) colonies in methylcellulose cultures in the presence of granulocyte-monocyte colony stimulating factor (GM-CSF) and erythropoietin (EPO), respectively, compared with control (Figures 2e and f) . Those MPD phenotypes are similar to pI-pC-injected primary untransplanted KM mice. [5] [6] [7] However, there were three main differences between pI-pC-injected recipients of Pggt1b fl/ þ KM fetal liver cells and primary KM mice. First, as expected, the transplanted mice did not develop tumors in nonhematopoietic tissues. Thus, the main goal of using a transplant approach was fulfilled. Second, the MPD phenotypes were attenuated in the transplanted mice: tissue infiltration of myeloid cells was much less pronounced compared with primary KM mice and bone marrow cells from the transplanted mice produced very few CFU-GM and no BFU-E colonies in the absence of growth factors (bone marrow cells from primary KM mice exhibit robust growth-factor-independent colony growth). The third difference was that all pI-pC-injected recipients of Pggt1b fl/ þ KM cells developed aggressive T-ALL with enlarged thymuses and striking lymphoblast infiltration in hematopoietic and peripheral tissues such as lung, liver (Figure 2g ), mucosal linings and skeletal muscle; in contrast, only 10-30% of primary KM mice develop T-ALL with enlarged thymuses but with only moderate lymphoblast infiltration in peripheral tissues. A high incidence of aggressive T-ALL was observed in earlier studies when bone marrow cells or isolated hematopoietic progenitors from pI-pC-injected primary KM mice were transplanted to secondary recipients. [8] [9] [10] Thus, whereas primary KM mice primarily develop MPD, the transplanted mice primarily develop T-ALL regardless of whether K-RAS G12D expression is switched on by pI-pC before transplantation as in earlier studies [8] [9] [10] or after transplantation as in the current study. One potential explanation for why the primary mice primarily develop MPD is that K-RAS G12D expression in nonhematopoietic cells in the bone marrow microenvironment might stimulate myeloid or suppress lymphoid expansion.
The inactivation of Pggt1b in K-RAS G12D -expressing hematopoietic cells (that is, in recipients of Pggt1b fl/D KM cells) reduced white blood cell counts, splenomegaly, and the percentage of CD13-and CD11b-positive cells, and increased the percentage of CD3-positive cells compared with recipients of Pggt1b fl/ þ KM cells (Figures 2a-c) . Moreover, the absence of Pggt1b reduced GM-CSF and EPO-induced colony growth in methylcellulose (Figures 2e and f) and resulted in increased expression of p21 expression is one proposed mechanism of tumor growth inhibition by GGTase-I inhibitors. 11, 12 Despite the significant inhibition of MPD phenotypes by Pggt1b inactivation, pI-pCinjected recipients of Pggt1b fl/D KM cells still developed aggressive T-ALL (Figure 2g ) and survival did not increase significantly (median 109 days; P40.05 versus Pggt1b fl/ þ KM recipients, logrank test; Figure 2d ). There was robust staining for nonprenylated RAP1A in the thymus and lymphoid infiltrates of the liver as judged by immunohistochemistry suggesting that GGTase-I was inactivated in many, but not all, T-ALL cells (Figure 2g , right panel). This staining pattern was similar to lung tumors of Pggt1b fl/D KL mice where the inactivation of GGTase-I significantly reduced tumor development and improved survival (not shown; Sjogren et al. 4 ). One potential explanation for the lack of effect of GGTase-I inactivation on survival is that the absence of GGTase-I has a significant impact on MPD phenotypes (Figures 2a-c, e and f) but no impact on T-ALL development and lymphoblast infiltration (Figure 2g ). This argument is supported by the observation that the main cause of death of these mice appears to be T-ALL and not MPD. However, we ca not rule out the possibility that the lack of effect of GGTase-I inactivation on survival was caused by outgrowth of rare clones in which Cre recombination occurred in the Kras2 locus but not in the Pggt1b locus (which would produce Pggt1b
M that retained the functional Pggt1b fl allele). The early death of two pI-pC-injected recipients of Pggt1b fl/D KM cells (Figure 2d ) prompted us to assess whether inactivation of GGTase-I might lead to acute toxicity. However, mice transplanted with Pggt1b fl/D M cells had normal white blood cell counts 9 days after pI-pC injections and the colonyforming ability did not differ from control (Supplementary Figure) .
We conclude that pI-pC injections in mice transplanted with Pggt1b fl/ þ KM fetal liver cells result in aggressive T-ALL against a background of MPD. The advantage of the approach is that K-RAS G12D expression is not activated in the fetal liver cells before transplantation and that it eliminates the multiple tumor types in nonhematopoietic tissues that arise in primary KM mice. We further conclude that knockout of Pggt1b inhibits MPD phenotypes but has little or no impact on T-ALL, suggesting that GGTase-I inhibitors could be tested in the treatment of MPDs such as JMML and CMML. The impact of inactivating GGTase-I on K-RAS-induced MPD in this study can likely be generalized to MPDs with N-RAS mutations, which are more frequent. Both N-and K-RAS are normally farnesylated by farnesyltransferase and the prenylation of these proteins are not affected by inactivating GGTase-I. The anticancer effect of inactivating GGTase-I results from defective prenylation of other CAAX proteins, such as the RHO family proteins.
